These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Discover the FDA-approved indications for GLP-1 receptors, including diabetes, weight loss, and cardiovascular disease. Learn brand-name and generic options.

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

It’s estimated 5.3 million Medicare members use the 15 drugs selected today. They account for $41 billion, or 14% of part D spending, from Nov. 1, 2023, to Oct. 31, 2024. GLP-1 drug costs over ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...

The GLP-1 compound drug sold by Hims and Hers is not approved by the FDA and its Super Bowl ad fails to list any risks ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...